Table 3. Visual Analogue Scale (VAS) evaluations of Group I and Group II.
Group I | Group II | |||||||
---|---|---|---|---|---|---|---|---|
Mean ± SD | Med (Min–Max) | Mean ± SD | Med (Min–Max) | |||||
VAS | ||||||||
Pre-injection | 7.2 ± 1.2 | 7 | 5–9 | 7.4 ± 1.1 | 7 | 4–9 | ||
1 month | 3.6 ± 0.5 | 4* | 3–4 | 3.7 ± 0.8 | 4* | 1–5 | ||
3 months | 3.5 ± 0.5 | 3* | 3–4 | 3.0 ± 0.7 | 3* | 1–4 | ||
6 months | 2.7 ± 0.5 | 3* | 2–3 | 2.6 ± 0.5 | 3* | 2–3 |
Mann-Whitney U test/Wilcoxon test. *Significant difference (p˂0.05) when compared to the pre-injection evaluation of the same group